After adding CD70 CAR-TOAd−GFP cells to GBM cells, the antitumor efficacy against GBM cells progressively increased over 72 h and significantly surpassed that of CD70 CAR-T cells following 72 h of co-culture (Fig. 2A). The gene discussed is CD70; the disease is glioblastoma.